The liver in Hodgkin's disease—I. Clinico-pathological relations

Brinckmeyer, L.M.; Skovsgaard, Torben; Thiede, T; Vesterager, L; Nissen, Nis I.

doi:10.1016/0277-5379(82)90109-2

Cited by 16 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, bone affectation is also associated to a high progression degree (HR: 1,96) [25]. However, in a patient with fever of unknown origin (FUO), highly elevated Alkaline Phosphatase and normal/slightly elevated serum transaminase levels suggest the possibility of lymphoma [26][27][28].…”

Section: Discussionmentioning

confidence: 99%

On the prediction of Hodgkin lymphoma treatment response

et al. 2015

View full text Add to dashboard Cite

-Martínez, jlfm@uniovi.es, 0034 985 103 199. AbstractPurpose: The cure rate in Hodgkin Lymphoma is high, but the response along the treatment is still unpredictable and is highly variable among patients. Detecting those patients that do not respond to the treatment at early stages could bring improvements in their treatment. This research tries to identify the main biological prognostic variables currently gathered at diagnosis, and designing a simple machine learning methodology to help physicians improving the treatment response assessment. Methods: We carried out a retrospective analysis of the response to treatment for a cohort of 263 Caucasians who were diagnosed with Hodgkin Lymphoma in Asturias (Spain). For that purpose, we used a list of 35 clinical and biological variables that are currently measured at diagnosis, before any treatment begins. To establish the list of most discriminatory prognostic variables for the treatment response we designed a machine learning approach based on two different feature selection methods (Fisher's ratio and Maximum Percentile Distance) and recursive feature elimination using a nearest-neighbor classifier (k-NN). The weights of the k-NN classifier are optimized using different terms of the confusion matrix (true and false positive rates) in order to minimize risk in the decisions. Results and conclusions: We found that the optimum strategy to predict treatment response in Hodgkin lymphoma consists in solving two

show abstract

Section: Discussionmentioning

confidence: 99%

On the prediction of Hodgkin lymphoma treatment response

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The available number of patients was small (133 patients with HD, 20 of them with LI), so that this result is uncertain. On the other hand, it was found that the Ann Arbor criteria for LI, namely hepatomegaly plus an elevated alkaline phosphatase level and elevation of two liver function tests or an abnormal liver scan and at least one abnormal liver function test, are not accurate in all cases [4,13,18].…”

Section: Introductionmentioning

confidence: 96%

“…Efforts have been made to identify clinical or laboratory features associated with LI [4,14]. Some clinical parameters found to be related to LI were: liver and/or spleen enlargement, elevated bromosulfophthalein (BSP) retention at 45 min, elevated aspartate aminotransferase (S-GOT), elevated serum alkaline phosphatase (SAP), positive lymphography and liver isotopic scan.…”

Section: Introductionmentioning

confidence: 99%

How to restrict liver biopsy to high-risk patients in early-stage Hodgkin's disease

Lieberz

Sextro

Paulus

et al. 2000

Annals of Hematology

View full text Add to dashboard Cite

Liver biopsy is an invasive diagnostic method for detecting liver involvement (LI) in Hodgkin's disease (HD). The aim of this retrospective study was to determine and evaluate a method for restricting liver biopsy to a subset of patients. Between 1988 and 1994, a total of 2,016 patients with HD were treated within the HD4-6 study protocol of the German Hodgkin's Lymphoma Study Group (GHSG). We investigated the predictive power of abdominal ultrasound (US) and computed tomography (CT), as well as of various clinical factors related to LI, using univariate and multivariate methods. LI occurred in 4.9% of all patients (99/2,016) and in 3.0% of those who, if LI were disregarded, would have been included in clinical stages I and II. In multivariate analysis the presence of LI was significantly associated with splenic involvement or infradiaphragmatic involvement, absence of mediastinal involvement, serum alkaline phosphatase (SAP) level over 230 units/l, and age over 40 years. We used these factors to define a risk score for LI. LI is very rare in patients who would otherwise be in clinical stages I or II, but knowledge of LI is important because it has therapeutic consequences. With our risk score, liver biopsy is indicated for approximately one quarter of these patients otherwise in clinical stages I or II.

show abstract

Hepatic Manifestations of Systemic Disorders

Gordon

Patel

2011

Schiff's Diseases of the Liver

View full text Add to dashboard Cite

The liver in Hodgkin's disease—I. Clinico-pathological relations

Cited by 16 publications

References 10 publications

On the prediction of Hodgkin lymphoma treatment response

On the prediction of Hodgkin lymphoma treatment response

How to restrict liver biopsy to high-risk patients in early-stage Hodgkin's disease

Hepatic Manifestations of Systemic Disorders

Contact Info

Product

Resources

About